The PennZone

  • Home
  • Non-profit
  • Education
  • Business
  • Construction
  • Entertainment
  • Technology
  • Health
  • Software

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • Why Athletic Recovery Begins in the Nervous System
  • A Hidden Magical World Awaits in Ashley Gayheart's Upcoming Young Adult Fantasy, Rosewood Academy: The Awakening
  • "I'm Sicka Church Too: Give Me Kingdom!" Ignites a Powerful Call for Healing and Truth
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • Premiere Venue Group Announces $25,000 Sponsorship to Support Ann's Heart Programs and Events
  • L2 Aviation Awarded IDIQ Contract by the U.S. Army for M1A2 Abrams Tank
  • Sycor.Rental Named Among 2026 Best Microsoft Dynamics ERP Supply Chain Solutions
  • KDG Redefines Enterprise Software Development with AI-Assisted and Agentic Delivery Model
  • Beyond Medication: Kellyn Foundation And Highmark Wholecare Tackle Type 2 Diabetes, Obesity With Comprehensive Lifestyle Program

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • 5,521 College Athletes Launch Own Merch Stores in Just 30 Days on AthleteMerch.com, Reaching 7,975 Live Storefronts Nationwide
  • Altruvest and Financial Executives International Canada Announce Strategic Partnership to Strengthen Nonprofit Boards Across Canada
  • Dr. Dee for the People: A Vision of Hope, Healing, and Transformation for Philadelphia
  • Free Critical Illness Claim Calculator Launches to the Public
  • Best Companies Group Launches Free Best Banks to Work For Program
  • I Voted Tvocracy and I Voted Radiocracy
  • Tolle Lege Learning Launches Publishing House to Revolutionize Early Learning Initiatives
  • HRC Fertility Celebrates Beverly Hills Grand Opening, Spotlighting Fertility Care as Women's Health Month Begins
  • HRC Fertility's Dr. Christo G. Zouves Appointed to San Mateo County Medical Association Board of Directors
  • HealthBook+ and Stonebrook Risk Solutions Partner to Bring Predictive Intelligence to Healthcare Risk
  • Umbrella Becomes First FinOps Platform to Support AWS Billing Transfer Onboarding
  • RECYCLEXPERT FZE Strengthens Leadership in Data Destruction UAE and GCC with Certified Secure ITAD Services
  • Plasma-Activated Nitric Oxide Cream Outperforms L-Arginine Skincare - New Research Explains Why
  • Assymetrix Launches the Deepest Independent Prediction Market Data API
  • CCHR: 'Plant-Based' Psychedelics Push Masks Synthetic Drugs and Billion-Dollar Profits
  • BTR: i2 Group Launches i2 Amplify, a Community Platform for Intelligence Professionals Worldwide
  • L.A. Watts Summer Games Announces Free Pelé Tribute Event at Magic Johnson Park
  • SUMOFIBER Fuels Explosive Growth With netElastic vBNG
  • Brian Keenan Joins ALLY Construction Services as Director of Business Development
  • Burkentine Builders Recognizes Local Fire Departments As Part Of Their Live With Purpose Initiative

Popular on PennZone

  • The Finger Comb, a Dream Inspired 3-in-1 Styling Tool introduced by Andrea L. Randolph - 121
  • From Speech Therapy to 300+ Episodes: Brother Marcus Turns His Voice Into a Movement Launching a 24/7 Inspiration Radio Network on Day 100 of the Year - 101
  • Mensa Brings National Board Game Competition to Northern Virginia April 16-19
  • Porter's Day Care Empowers Philadelphia's Future Through 45+ Years of Excellence
  • Bishop Mary's WWDB 860 AM Show Nears Historic 250-Episode Milestone
  • Dog Grooming Businesses Turn to Performance-Based Platforms to Attract Local Clients
  • Eastern Adjustment Group, LLP Provides Property Loss Advocacy and Claim Support
  • Bold Beauty Project Announces Exhibition at Palazzo Mora Venice, Italy
  • New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
  • A Powerful Beginning Inside One of Philadelphia's Most Inspiring Early Childhood Education Centers

Similar on PennZone

  • NRx Pharmaceuticals (N A S D A Q: NRXP) Accelerates Into National Spotlight as Manufacturing Launch, Federal Policy & AI-Driven Breakthroughs Converge
  • More Life Summit 2026 Announces Gary Brecka & Mr. Olympia Derek Lunsford as First Speakers for Miami Event
  • Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Charging Into the $30 Billion Heart Failure Market with Late-Stage Momentum, Breakthrough Data, & Strong Financial Backing: Cardiol Therapeutics $CRDL
  • Instant IP Teams: Bringing Enterprise-Grade Collaboration to IP Protection at the Speed of Thought
  • Boston Industrial Solutions Expands Its Industry-Leading UV Ink Portfolio with the Launch of a Matte Ink - Natron® UVPZ
  • AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
  • NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us